About
Technology
Issues
FAQ
Links
Official Page
DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
site/software ©
exaly
; All materials licenced under
CC by-SA
.